Aerovate Therapeutics Reports Exit Costs

TL;DR

Aerovate's filing signals potential business wind-down or restructuring.

AI Summary

On June 25, 2024, Aerovate Therapeutics, Inc. filed an 8-K report detailing costs associated with exit or disposal activities. The company, incorporated in Delaware, is based in Waltham, Massachusetts, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates potential restructuring or discontinuation of certain operations within Aerovate Therapeutics, which could impact its future business strategy and financial performance.

Risk Assessment

Risk Level: medium — Filings related to exit or disposal activities often suggest significant business changes or challenges that could affect the company's stability and future prospects.

Key Numbers

• 001-40544 — SEC File Number (Identifies the company's filing with the SEC.)
• 83-1377888 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Aerovate Therapeutics, Inc. (company) — Registrant
• June 25, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Waltham, Massachusetts (location) — Principal executive offices
• 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share AVTE The Nasdaq
• $5.6 m — ideration of releases) of approximately $5.6 million, which are primarily one-time sev

Filing Documents

• tmb-20240625x8k.htm (8-K) — 43KB
• 0001798749-24-000036.txt ( ) — 165KB
• tmb-20240625.xsd (EX-101.SCH) — 3KB
• tmb-20240625_lab.xml (EX-101.LAB) — 16KB
• tmb-20240625_pre.xml (EX-101.PRE) — 11KB
• tmb-20240625x8k_htm.xml (XML) — 5KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On June 25, 2024, Aerovate Therapeutics, Inc. (the "Company") determined to implement a reduction of the Company's workforce (the "Workforce Reduction Plan") following the Company's previously announced decision to shut down its Phase 2b/Phase 3 clinical trial of AV-101 as well as the long-term extension study. Under the Workforce Reduction Plan, the Company intends that nearly all of its workforce will be terminated in the coming months. The Company initiated the first wave of its Workforce Reduction Plan by notifying 39 individuals, or 78% of the Company's workforce, of their termination. The affected individuals will be provided severance benefits, including cash severance payments. Each affected individual's eligibility for severance benefits is contingent upon entering into a separation agreement, which includes a general release of claims against the Company. In connection with the Workforce Reduction Plan, the Company estimates that it will be incurring costs (in consideration of releases) of approximately $5.6 million, which are primarily one-time severance benefits. These costs are expected to be incurred in the third and fourth quarter of 2024. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "future," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," seek," "strategy," "should," "target," "will," "would" and similar expressions regarding future periods. These forward-looking statements include, but are not limited to, statements regarding the estimated costs expected to be incurred in connection with the Workforce Reduction Plan and related severance payments. Any fo

View Full Filing

View this 8-K filing on SEC EDGAR